Drax Group Earnings Calls
| Release date | Feb 26, 2026 |
| EPS estimate | $0.82 |
| EPS actual | $0.82 |
| Revenue estimate | 4.252B |
| Revenue actual | 4.252B |
| Release date | Jul 31, 2025 |
| EPS estimate | - |
| EPS actual | $0.409 |
| Revenue estimate | - |
| Revenue actual | 1.804B |
| Release date | Jul 24, 2025 |
| EPS estimate | - |
| EPS actual | - |
| Revenue estimate | - |
| Revenue actual | - |
| Release date | Feb 27, 2025 |
| EPS estimate | - |
| EPS actual | $0.599 |
| Revenue estimate | - |
| Revenue actual | 3.878B |
Last 4 Quarters for Drax Group
Below you can see how DRXGF performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Feb 27, 2025 |
| Price on release | $7.93 |
| EPS estimate | - |
| EPS actual | $0.599 |
| Date | Price |
|---|---|
| Feb 21, 2025 | $7.84 |
| Feb 24, 2025 | $7.84 |
| Feb 25, 2025 | $7.84 |
| Feb 26, 2025 | $8.20 |
| Feb 27, 2025 | $7.93 |
| Feb 28, 2025 | $7.93 |
| Mar 03, 2025 | $7.92 |
| Mar 04, 2025 | $7.66 |
| Mar 05, 2025 | $7.66 |
| 4 days before | 1.15% |
| 4 days after | -3.40% |
| On release day | -1.13% |
| Change in period | -2.30% |
| Release date | Jul 24, 2025 |
| Price on release | $9.19 |
| EPS estimate | - |
| EPS actual | - |
| Date | Price |
|---|---|
| Jul 18, 2025 | $7.50 |
| Jul 21, 2025 | $9.19 |
| Jul 22, 2025 | $9.19 |
| Jul 23, 2025 | $9.19 |
| Jul 24, 2025 | $9.19 |
| Jul 25, 2025 | $7.50 |
| Jul 28, 2025 | $9.19 |
| Jul 29, 2025 | $9.19 |
| Jul 30, 2025 | $9.19 |
| 4 days before | 22.53% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | 22.53% |
| Release date | Jul 31, 2025 |
| Price on release | $9.19 |
| EPS estimate | - |
| EPS actual | $0.409 |
| Date | Price |
|---|---|
| Jul 25, 2025 | $7.50 |
| Jul 28, 2025 | $9.19 |
| Jul 29, 2025 | $9.19 |
| Jul 30, 2025 | $9.19 |
| Jul 31, 2025 | $9.19 |
| Aug 01, 2025 | $7.50 |
| Aug 04, 2025 | $9.19 |
| Aug 05, 2025 | $9.19 |
| Aug 06, 2025 | $9.19 |
| 4 days before | 22.53% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | 22.53% |
| Release date | Feb 26, 2026 |
| Price on release | $11.10 |
| EPS estimate | $0.82 |
| EPS actual | $0.82 |
| Date | Price |
|---|---|
| Feb 20, 2026 | $11.10 |
| Feb 23, 2026 | $11.10 |
| Feb 24, 2026 | $11.10 |
| Feb 25, 2026 | $11.10 |
| Feb 26, 2026 | $11.10 |
| Feb 27, 2026 | $11.10 |
| Mar 02, 2026 | $11.10 |
| Mar 03, 2026 | $11.10 |
| Mar 04, 2026 | $11.10 |
| 4 days before | 0% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | 0% |
Drax Group Earnings Call Transcript Summary of Q4 2025
Key points for investors: Drax delivered a strong 2025 operational and financial performance (record renewable generation and pellet production) and signed a post‑2027 low‑carbon dispatchable CfD for Drax Power Station — a milestone that management says underpins the business through 2031. The group reiterates its plan to generate roughly £3.0bn of free cash flow between 2025–2031, with an initial allocation of over £1.0bn to shareholder returns (dividends + buybacks) and up to about £2.0bn targeted for growth investments. Growth priorities are a UK‑focused FlexGen expansion (gigawatt‑scale BESS pipeline, control/agreements for >700 MW of batteries, plus tolling deals and Flexitricity acquisition for optimization) and potential development of data centre capacity at Drax Power Station (plans discussed for ~100 MW near term and up to ~1 GW+ over phases). FlexGen also includes pumped storage/hydro (Cruachan) upgrades and new open‑cycle gas assets with capacity market support. The pellet business is being reframed: U.S. South operations are resilient and being integrated with generation, while the Canadian pellet business faces structural challenges — management took impairments, paused Longview and is reviewing strategic options. Cost discipline is a focus: structural savings target of >£150m pa by 2027 (these are built into the £600–700m post‑2027 EBITDA target). Balance sheet and shareholder returns: adjusted EBITDA £947m in 2025, net debt £784m (~0.8x 2025 EBITDA), strong cash/facilities (~£942m), a guidance‑consistent dividend increase (expected 29p, +11.5%) and ongoing buyback programs. Risks/notes: impairments related to Canadian pellets and BECCS development write‑down; new CfD will change operating profile from 2027; growth investments (batteries, data centre, renewables) are being phased and some returns are medium‑term.
Sign In
Buy DRXGF